The rapidly rising costs of cancer care, driven in particular by the high prices of new drugs, are increasingly challenging health-care systems across the world. To ensure accessibility to novel antitumour drugs, novel paradigms are needed at several levels, not only economically, but also in terms of research and new study designs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Eijsden, P. Fate of new cancer drug is uncertain in Netherlands, as institute deems it too costly. BMJ 351, h6778 (2015).
van Harten, W. H., Wind, A., de Paoli, P., Saghatchian, M. & Oberst, S. Actual costs of cancer drugs in 15 European countries. Lancet Oncol. 17, 18–20 (2016).
Beije, N., Jager, A. & Sleijfer, S. Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment? Cancer Treat. Rev. 41, 144–150 (2015).
Sickinger, M. T. et al. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma. Cochrane Database Syst. Rev. 1, CD010533 (2015).
Davar, D., Socinski, M. A., Dacic, S. & Burns, T. F. Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. Exp. Hematol. Oncol. 4, 34 (2015).
Sleijfer, S., Bogaerts, J. & Siu, L. L. Designing transformative clinical trials in the cancer genome era. J. Clin. Oncol. 31, 1834–1841 (2013).
Cherny, N. I. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann. Oncol. 26, 1547–1573 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Rights and permissions
About this article
Cite this article
Sleijfer, S., Verweij, J. Affordability of drugs used in oncology health care. Nat Rev Clin Oncol 13, 331–332 (2016). https://doi.org/10.1038/nrclinonc.2016.77
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.77
